SAB Biotherapeutics, Inc. (SABS): Revenue
Partial revenue. In this company's filings, reported revenue for the year ended 2025-12-31 is zero or negative beside a profit. The revenue it tags covers only part of its income (banks and REITs often tag only fee income this way, leaving out interest or rent), so it is not the company's whole top line. Margins on it are not computed, and it is left out of revenue rankings.
$0
Year ended 2025-12-31
| Period ended | Revenue | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $0 | -100.0% | 2026-03-09, From 2025-01-01 |
| 2024-12-31 | $1.32M | -40.9% | 2026-03-09, From 2024-01-01 |
| 2023-12-31 | $2.24M | -90.6% | 2025-03-31, From 2023-01-01 |
| 2022-12-31 | $23.90M | -60.7% | 2024-03-29, From 2022-01-01 |
| 2021-12-31 | $60.88M | +10.2% | 2023-04-28, From 2021-01-01 |
| 2020-12-31 | $55.24M | n/a | 2023-04-28, From 2020-01-01 |